Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This randomized controlled trial evaluates whether molecular hydrogen supplementation enhances the effectiveness of a 4-week weight loss retreat in overweight and obese adolescents. Outcome measures include: body composition, physical status, blood samples (insulin sensitivity, lipid profiles, markers of oxidative stress and inflammation) and autonomic nervous system function.
The aim of this randomized, double-blind, parallel-group, placebo-controlled trial is to evaluate whether molecular hydrogen supplementation enhances the effectiveness of weight loss retreat for overweight and obese adolescents. Weight loss retreat is indicated for participants based on diagnosis and recommendation of a pediatrician. During the 4-week retreat, participants follow a prescribed standardized intervention consisting of reduction diet and physical activity. The total planned number of participants is 60. Participants are randomly divided into two balanced groups, with one group receiving molecular hydrogen in the form of hydrogen-rich water and the other receiving a placebo water. The daily amount of water given (hydrogen-rich or placebo) is 1.5 L. Hydrogen-rich water is packaged in specially designed aluminum containers to minimize hydrogen leakage and ensure long-term stability with a dissolved hydrogen concentration of 1.2-1.6 ppm. Participants are unable to distinguish hydrogen-rich water from the placebo because molecular hydrogen is colorless, odorless, and tasteless. Participants monitor their physical activity, sleep, and sedentary behavior one week before to retreat and undergo baseline diagnostics (including blood sampling), three weekly interim diagnostics during retreat, and final diagnostics (including blood sampling) after four weeks. If participants are available, two follow-up diagnostics are conducted six weeks and six months after the retreat and include seven-day monitoring of physical activity, sleep, and sedentary behavior. Statistical analysis is performed at a significance level of α = 0.05 and the data is evaluated using analysis of variance. In cases of non-normality, data transformations or non-parametric alternatives are used.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Molecular hydrogen | Experimental | Supplementation with molecular hydrogen in the form of hydrogen-rich water administered 1.5 L per day - before breakfast (500 ml), lunch (500 ml) and dinner (500 ml). |
|
| Placebo | Placebo Comparator | Supplementation with drinking water administered 1.5 L per day - before breakfast (500 ml), lunch (500 ml) and dinner (500 ml). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hydrogen-rich water | Dietary Supplement | Hydrogen-rich water with molecular hydrogen concentration 1.2-1.6 ppm. No added sugar or preservatives. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Body mass index | Body mass index is calculated as the ratio of body mass (kg) to the square of body height (m2). Body mass is measured using a digital scale to the nearest 0.1 kg and body height is measured using a stadiometer to the nearest 1 cm. | Baseline and 4 weeks |
| Six-minute walk test | Six-minute walk test is measured by recording the total distance the participant is able to walk on a flat surface within six minutes. The participant is instructed to walk at his/her own pace in order to walk as far as possible in the given time. | Baseline and 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Body fat | Body fat is measured using bioelectrical impedance analysis (InBody 270, InBody, Seoul, South Korea). | Baseline and 4 weeks |
| 30-second sit-to-stand test | 30-second sit-to-stand test is measured by counting the number of repetitions in which the participant rises from sitting in a chair and sits back down within 30 seconds. |
| Measure | Description | Time Frame |
|---|---|---|
| Waist circumference | Waist circumference is be measured at the narrowest part of the torso, above the iliac crest and below the lowest rib, using a non-elastic tape. | Baseline and 4 weeks |
| Blood pressure |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Darja Supikova | Palacky University, Faculty of Physical Culture | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Palacky University, Faculty of Physical Culture | Olomouc | Czech Republic | 77111 | Czechia |
All IPD that underlie results in a publication.
Not provided
Beginning 1 year after the publication of results with no end date.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | Drinking water with molecular hydrogen concentration 0.0 ppm. No added sugar or preservatives. |
|
|
| Baseline and 4 weeks |
| Maximal isometric grip force | Maximal isometric grip force is measured using a hand dynamometer. The test is performed seated, with the elbow flexed at 90 degrees, and wrist in a neutral position. | Baseline and 4 weeks |
| Maximal wall sit | Maximal wall sit is measured by recording the maximum duration for which the participant can maintain a static isometric squat position against a wall. | Baseline and 4 weeks |
| Resting blood lactate | The level of resting blood lactate is measured using the Lactate Scout+ (EKF Diagnostics, Cardiff, United Kingdom). Capillary blood is collected in a fasting state from the fingertip using a sterile disposable lancet. Immediately after collection, the blood sample is applied to the test strip of the lactate meter and analyzed in real time. | Baseline and 4 weeks |
| Homeostatic model assessment of insulin resistance | Homeostatic model assessment of insulin resistance is calculated based on fasting glucose and fasting insulin levels measured from blood samples obtained via venipuncture by a healthcare specialist. Plasma glucose is separated by centrifugation and analyzed using an enzymatic colorimetric method. Serum insulin is separated by centrifugation and analyzed using a chemiluminescent immunoassay. | Baseline and 4 weeks |
| Total cholesterol | The level of total cholesterol is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation and analyzed using an enzymatic colorimetric method. | Baseline and 4 weeks |
| Low-density lipoprotein | The level of low-density lipoprotein is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation and analyzed using an enzymatic colorimetric method. | Baseline and 4 weeks |
| High-density lipoprotein | The level of high-density lipoprotein is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation and analyzed using an enzymatic colorimetric method. | Baseline and 4 weeks |
| Triglycerides | The level of triglycerides is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation and analyzed using an enzymatic colorimetric method. | Baseline and 4 weeks |
| Cortisol | The level of cortisol is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The serum is separated by centrifugation and analyzed using a chemiluminescent immunoassay. | Baseline and 4 weeks |
| Fibroblast growth factor 21 | The level of fibroblast growth factor 21 is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until ELISA analysis. | Baseline and 4 weeks |
| Total antioxidant capacity | The level of total antioxidant capacity is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until analysis using the TROLOX equivalent antioxidant capacity assay. | Baseline and 4 weeks |
| Malondialdehydes | The level of malondialdehydes is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until ELISA analysis. | Baseline and 4 weeks |
| Protein carbonyls | The level of protein carbonyls is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until ELISA analysis. | Baseline and 4 weeks |
| Interleukin-6 | The level of interleukin-6 is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until ELISA analysis. | Baseline and 4 weeks |
| Tumor necrosis factor alpha | The level of tumor necrosis factor alpha is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until ELISA analysis. | Baseline and 4 weeks |
Blood pressure is measured using a mercury sphygmomanometer.
| Baseline and 4 weeks |
| Hydration Status | Hydration status is assessed by measuring the urine specific gravity of morning urine sample using a refractometer (SUR-NE, ATAGO, Tokyo, Japan). | Baseline and 4 weeks |
| Subjective evaluation of lower limb soreness | Subjective evaluation of lower limb soreness is measured using a Visual Analog Scale before and after a wall-sit exercise, with the duration individually adjusted to 65% of each participant's maximum hold time. The Visual Analog Scale consists of a 100 mm line ranging from 0 mm (no soreness) to 100 mm (unbearable soreness). | Baseline and 4 weeks |
| Heart rate variability | Heart rate variability is measured using an ECG device (DiANS PF8, DIMEA Group, Olomouc, Czech Republic). ECG recording is performed during the orthoclinostatic maneuver in a calm room without acoustic and visual disturbances. | Baseline and 4 weeks |
| Physical Activity Level | The level of physical activity is assessed using a wrist-worn tri-axial accelerometer (AX3, Axivity, Newcastle, United Kingdom). This accelerometer provides detailed data on the intensity, frequency, and duration of physical activity. | Baseline and 4 weeks |
| Sedentary Behavior | Sedentary behavior is assessed using a wrist-worn tri-axial accelerometer (AX3, Axivity, Newcastle, United Kingdom). This accelerometer identifies frequency and duration of sedentary bouts. | Baseline and 4 weeks |
| Sleep duration | Sleep duration and quality is assessed using a wrist-worn tri-axial accelerometer (AX3, Axivity, Newcastle, United Kingdom). This accelerometer detects sleep patterns and provides total sleep time, sleep efficiency, and the timing of sleep periods. | Baseline and 4 weeks |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided